GeneDx Holdings

GeneDx Holdings PP&E per Employee

The PP&E per Employee of GeneDx Holdings (WGS) as of Oct 29, 2026 is 64,834.62 USD. In the previous year, PP&E per Employee was 48,245.38 USD — a change of 34.39% (higher).

PP&E per Employee

64,834.62USD

YoY

34.39%

Last updated:

PP&E per Employee of GeneDx Holdings is 2022 64,834.62 USD. PP&E per Employee of GeneDx Holdings was 2021 48,245.38 USD. It decreases by 34.39% higher compared to the previous year.

The GeneDx Holdings PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2019
27,125.38 USD
Jan 1, 2020
48,546.15 USD
Jan 1, 2021
48,245.38 USD
Jan 1, 2022
64,834.62 USD
The GeneDx Holdings PP&E per Employee history
YEARPP&E per EmployeeYoY
64,834.62USD+34.39%
48,245.38USD-0.62%
48,546.15USD+78.97%
27,125.38USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneDx Holdings Stock analysis

What does GeneDx Holdings do? GeneDx Holdings Corp. generates revenue through its GeneDx and Legacy Sema4 segments. The GeneDx segment offers pediatric and rare disease diagnostics, primarily utilizing whole exome and genome sequencing, along with data and information services. It provides genetic diagnostic tests, screening solutions, and information to clinicians and patients. The Legacy Sema4 segment delivers reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. Both segments target healthcare providers and institutions seeking personalized health insights for diagnosis, treatment planning, and drug discovery. The company’s products include genetic diagnostic tests, screening solutions, and information services under the GeneDx brand, while Legacy Sema4 focuses on reproductive health, women’s health, and oncology diagnostics. These services are sold to healthcare providers and institutions that require actionable health intelligence to inform clinical decisions and improve patient outcomes. The segments serve distinct medical specialties, with GeneDx emphasizing rare diseases and pediatric care, and Legacy Sema4 covering reproductive health and cancer diagnostics. Revenue is derived from diagnostic testing services provided through both segments. The GeneDx segment’s core offerings are whole exome and genome sequencing for rare and pediatric conditions, while Legacy Sema4 specializes in reproductive, women’s health, and somatic oncology testing. These services are delivered to healthcare systems and providers who integrate genetic data into patient care pathways for better diagnosis and treatment strategies. GeneDx Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneDx Holdings stock

PP&E per Employee of GeneDx Holdings is 64,834.62 USD in 2022.

PP&E per Employee of GeneDx Holdings changed from 48,245.38 USD to 64,834.62 USD, representing a 34.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee GeneDx Holdings since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's GeneDx Holdings historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — GeneDx Holdings

All Key Metrics — GeneDx Holdings